Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. - Wikidata - awgldk - TriplyDB

Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.

Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.

http://www.wikidata.org/entity/Q39636515

about

Class III β-tubulin counteracts the ability of paclitaxel to inhibit cell migration New insights into mechanisms of resistance to microtubule inhibitors Mechanisms of resistance in castration-resistant prostate cancer (CRPC)Targeting molecular resistance in castration-resistant prostate cancer Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies Nanoparticle-mediated drug delivery for treating melanoma The many faces of neuroendocrine differentiation in prostate cancer progression High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer βIII-Tubulin: biomarker of taxane resistance or drug target?Synergistic antitumor activities of docetaxel and octreotide associated with apoptotic-upregulation in castration-resistant prostate cancer Influence of Matrices on 3D-Cultured Prostate Cancer Cells' Drug Response and Expression of Drug-Action Associated Proteins Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.Microtubules and their role in cellular stress in cancer Tubulin Beta-3 Chain as a New Candidate Protein Biomarker of Human Skin Aging: A Preliminary Study.PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder.Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways Silencing Notch-1 induces apoptosis and increases the chemosensitivity of prostate cancer cells to docetaxel through Bcl-2 and Bax.Protein kinase A type II-α regulatory subunit regulates the response of prostate cancer cells to taxane treatment.Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects.Biomarkers for prostate cancer: present challenges and future opportunities.Overcoming docetaxel resistance in prostate cancer: a perspective review.Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities.Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness.The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target.High-level βIII-tubulin overexpression occurs in most head and neck cancers but is unrelated to clinical outcome.High levels of class III β-tubulin expression are associated with aggressive tumor features in breast cancer.Mechanisms of Therapeutic Resistance in Prostate Cancer.Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin.CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1.Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies.The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines.Establishment of a dog primary prostate cancer organoid using the urine cancer stem cells.The evolution of chemotherapy for the treatment of prostate cancer.[Biomarker docetaxel-based chemotherapy].βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel.Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.

P2860

Q24617268-8C3AFBFB-AD73-4D94-B593-35173341C8EF Q24633853-1663F9A1-A676-4311-A0FF-B24FE0D14285 Q26774221-897DDA60-511E-4B3F-B096-B6EC131C9C8A Q26795445-8599C2AB-1618-40CA-BCEA-F5934B100055 Q26796704-E2F8E8EC-1A67-45E9-A8A0-D1263DA16800 Q26798379-EBC01CF9-83F4-4C6C-88D2-7FF64EA0B622 Q26992049-85667308-FFA8-410A-AB96-13A62EDC0F3D Q27851983-E8564BA7-8636-4A20-A5C2-DBAF61B38B8A Q28284878-63746FA0-C1A6-47FA-AF80-210FA4F3920B Q28540917-1B247D92-8A55-4867-B5B0-2A0A7325964A Q28552225-826A45FB-1758-41C3-A68C-FA4BC5C0EAD6 Q30244818-CD5D22A5-B1BB-4AFC-9FA4-ACDD27BF8359 Q33770927-6320A39E-DC12-46DE-877F-5EA628F496F9 Q33775713-C047E83E-D2C9-4AC9-9502-B370E371CD7E Q35068026-A398F990-4922-4F97-B9B6-C66A0C14EE1B Q35273536-3AE4A4D5-0DAE-4BDA-BEC3-BFC421F26115 Q35653741-E95F91F1-0886-4887-B343-57F2DA278E73 Q35678695-E534303F-0756-4EE6-A493-5D08B83AC1CC Q35963384-F548929A-07FD-40C0-9CBD-9D1844C2ED91 Q35995318-9C841B57-137F-49CE-95D2-6A566FBA8F62 Q36188433-0DAB6CE7-8F81-4C25-BE92-100625E39F10 Q37303584-13F6BA3D-7DC5-4879-A3C3-6BAB03BF0382 Q37474443-C8B070E1-774F-4D44-B642-996E61487AA3 Q38057235-34E909B9-20EE-46FD-A9C1-F503104752CB Q38183686-529053D6-9504-4894-AB0F-5F8B966182AE Q38389933-7FB23D8A-FC47-45BD-ACD6-DDEF44F43600 Q38575004-23B9FC30-8DA1-42D6-8D2E-1845F61B0E9C Q38667965-641BB739-00A2-49D1-906D-18770EE8ABF4 Q38719315-AC5703D6-0DFE-43F8-BB4B-D5F436CDF25D Q38754316-BEB995F7-DE76-4161-A6E0-B9C91B8C4D5C Q38810389-1D4A4A6E-8F25-4678-B770-AD00C9C0A307 Q38943604-6910EA81-9A07-401C-A50D-1C75D8DA6E24 Q39105730-ABABD140-A6C2-46E3-8F99-11EFE18D5AAE Q39343181-ECCCEB16-87B1-4EED-8F13-E4E9C59F1C8A Q42516700-B4490C97-AC00-476B-B914-D55CE5252CDF Q45943517-E49CE0AF-F195-499B-AE27-BF91B962A479 Q46262484-DA0BBAF4-A4AA-4F50-B1E2-4FC2F93ED9BD Q46888914-211820C2-235F-4378-9E47-C884F9A93E64 Q47096886-2948B941-ECE8-4283-B019-C256EA55CAF7 Q50944315-2262D456-477E-481B-95AE-777504D96426

P2860

Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.

http://www.wikidata.org/entity/Q39636515

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Class III beta-tubulin express ...... docetaxel-based chemotherapy.

@en

Class III beta-tubulin express ...... docetaxel-based chemotherapy.

@nl

type

label

Class III beta-tubulin express ...... docetaxel-based chemotherapy.

@en

Class III beta-tubulin express ...... docetaxel-based chemotherapy.

@nl

prefLabel

Class III beta-tubulin express ...... docetaxel-based chemotherapy.

@en

Class III beta-tubulin express ...... docetaxel-based chemotherapy.

@nl

P1433

Q39636515-D9DADE4F-FCD7-42C5-BEC9-51AEE92E0363

P1476

Q39636515-DD3CB666-3F9B-4D76-8113-D0157857220F

P2093

Q39636515-1B6909B8-37A4-496C-8B51-C2B2BF5D0783

Q39636515-1D3B6728-68F9-49B6-B488-3F2520E26E8A

Q39636515-37ECAA7E-D809-4597-918B-5CA1C601DF93

Q39636515-3E7B1DAF-9A44-43AC-9F91-C77A4E612946

Q39636515-559C3F7B-606E-4C16-8417-203371C4B682

Q39636515-85CB7B1D-9AE9-41C2-8B53-62808175BF3D

Q39636515-8EEF259A-99B4-4F6E-82AC-D827526B3322

Q39636515-BED681BD-5B20-42ED-8F32-FCF233452C1E

Q39636515-C02C4714-D18A-47DF-A3D6-AEF66E58D97E

Q39636515-C43EBF16-AB96-48A6-9A83-E43429F59B12

P2860

Q39636515-0221BEBE-88CB-445A-AFB5-912BE9C5D17C

Q39636515-08402975-332E-4786-97FC-5C766DDDB2CE

Q39636515-0DBF21C9-2F0E-4560-AF7E-389240962FD7

Q39636515-0F730875-65CB-478A-AACF-CF6C9F3F9C6E

Q39636515-15827F73-AA65-4F2D-AB5C-D21AFB91564D

Q39636515-1AF954F6-BCD4-4212-A0BB-4B566CCBA61F

Q39636515-2C60067E-4706-48BA-9CBA-EB78B8F7D106

Q39636515-32FBF8F1-EEBD-4D57-8200-565CE7D38CFB

Q39636515-39B9F682-ACB9-4613-8BBA-9F4BD2A280D1

Q39636515-3E0EB28C-71F5-4545-ADB4-C5FF5AA0DD29

P304

Q39636515-8C11FAED-E003-4F67-9E6A-88137B2B56FC

P31

Q39636515-4E51F456-9A57-4928-8707-CE171D54D1AE

P356

Q39636515-440B57BC-E462-4392-A8E9-42CC09B86E70

P407

Q39636515-FE48BA49-C9FF-4E2C-9013-BA594AF3388E

P433

Q39636515-A5D3BD1C-1640-4679-9613-CA215FBB475F

P478

Q39636515-5F83AEC0-FB91-4FFA-B07A-A9E17B6F5B4D

P50

Q39636515-F9D43E5B-A226-4A04-AFD1-31417FAD7DB5

P577

Q39636515-97D3A5AC-75B8-45DD-A0E7-F333F417F454

P698

Q39636515-7942FF1B-9681-4D0D-BEA7-1276D4983A90

P921

Q39636515-3AAB7A7E-ABE8-42E0-8920-48DEE885698A

Q39636515-75D73D90-DD1E-4E8F-9AA2-87D0DD8DD87C

P932

Q39636515-6F149114-C9ED-41AF-9197-C1C309CF589E

P356

0008-5472.CAN-10-1447

P1433

Cancer Research

P1476

Class III beta-tubulin express ...... o docetaxel-based chemotherapy

@en

P2093

Alexandre de la Taille

http://www.w3.org/2001/XMLSchema#string

Bernard Paule

http://www.w3.org/2001/XMLSchema#string

Estelle Coppolani

http://www.w3.org/2001/XMLSchema#string

Francis Vacherot

http://www.w3.org/2001/XMLSchema#string

Guillaume Ploussard

http://www.w3.org/2001/XMLSchema#string

Laurence Kheuang

http://www.w3.org/2001/XMLSchema#string

Laurent Salomon

http://www.w3.org/2001/XMLSchema#string

Nanor Sirab

http://www.w3.org/2001/XMLSchema#string

Nathalie Nicolaiew

http://www.w3.org/2001/XMLSchema#string

Pascale Maillé

http://www.w3.org/2001/XMLSchema#string

P2860

Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer

Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel

Loss of class III beta-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells

Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells

Cancer statistics, 2009

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel.

Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer.

Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death.

P304

9253-9264

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-10-1447

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Stéphane Terry

P577

2010-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21045157

http://www.w3.org/2001/XMLSchema#string

P921

P932

3290526

http://www.w3.org/2001/XMLSchema#string